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Prognostic Signiﬁcance of Anemia in Patients Undergoing PCI with First and
Second Generation DES (Katowice Registry)
Wojciech Wojakowski1, Wojciech Wanha1, Aleksandra Pluta1, Kamil Marcinkiewicz1,
Jan Dola1, Damian Kawecki2, Beata Morawiac2, Lukasz Krzych1, Andrzej Ochala1,
Michal Tendera1
1Medical University of Silesia, Katowice, Poland, 2Medical University of Silesia,
Zabrze, Poland
Background: Anemia present prior to PCI is associated with an increased risk of
death, myocardial infarction (MI) and bleeding complications in particular in acute
coronary syndromes (ACS). Patients with anemia often do not receive recommended
by guidelines antithrombotic treatment and drug-eluting stents (DES) because of the
increased bleeding risk. Aim of this all-comer Katowice Registry is to compare 1-year
outcomes in patients with coronary artery disease (CAD) and anemia treated with PCI
with ﬁrst and second-generation DES.
Methods: We enrolled 1916 consecutive patients (65% males, mean age 63 y) pre-
senting with unstable angina (78%), NSTEMI (15%) and STEMI/LBBB MI (7%)
treated either with ﬁrst (paclitaxel, sirolimus) or second generation (everolimus,
zotarolimus, biolimus A9) DES (o-DES 34%; n-DES¼66%). Anemia was deﬁned
according to WHO [hemoglobin (Hb) level <13g/dL for men and <12g/dL for
women]. Incidence of MACCE (death, MI, stroke, repeat-revascularization) at 1-year
was a primary end-point of this study and was evaluated by telephone follow-up or
data from national ministry of health.
Results: The study population was stratiﬁed according to presence of anemia on
admission. Anemia was present in 11% of patients (microcytic 11%, normocytic 53%,
macrocytic 35%). Patients with anemia were older (6710 vs. 6210 years,
p<0.001), had diabetes (44% vs. 6%,p¼0,02), chronic kidney disease (32% vs. 15%,
p<0,001), PAD (17% vs. 10%, p¼0,005), carotid disease (10% vs. 5%, p¼0,006),
history of MI (57% vs. 46%,p¼0,002), CABG (31% vs. 19%,p¼0,0001), impaired
LEF (50 (40-57)% vs. 55 (45-60)%,p¼<0,001), higher GRACE score [>140 (75%
vs. 53%,p¼0,010) and more frequently had bleeding requiring transfusion (3,2% vs.
0,5%, p<0,001). Hospitalization was longer [5 (4-7) vs. 4 (3-6) days,p¼0,002]. Pa-
tients with anemia had more 3 vessel disease (36,4% vs. 26,1%,p¼0,001) and higher
SYNTAX [21(12-27) pkt. vs. 14(8-22) pkt. p¼0,001)]. Stent thrombosis in culprit
vessel was signiﬁcantly more frequent (1,7% vs. 0,3%, p¼0,037). In 1-year F-U there
was signiﬁcantly higher mortality (7,4% vs. 2,9%, p¼0,001) than in pts without
anemia. In patients treated with o-DES there was a trend to higher rate of CABG
during F-U (4,1% vs. 0,7%, p¼0,082). Univariate regression showed that anemia was
a predictive of death, however in multivariate regression model only eGFR, LVEF and
age, but not anemia (HR 1,23 95%CI 0,56-1,91) were independent predictors of death.
Despite higher disease burden in patients with anemia 1-year follow-up showed that
there was no difference in composite MACCE (death, MI, stroke, repeat-revascular-
ization) in comparison to patients with normal Hb (p¼0,60, Kaplan-Meyer). There
was also no difference according to type of DES (ﬁrst vs. new generation).
Conclusion: Anemia is relatively frequent (11%) in patients with CAD and associated
with higher 1-year mortality. Despite higher bleeding risk use of DES is safe to the
same extent as in patients without anemia.
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Background: Preexisting renal insufﬁciency was independent risk factors for
contrast-induced acute kidney injury (CI-AKI). One of the associated predisposing
factors for CI-AKI is a propensity for enhanced renal hypoxia. Urinary L-FABP levels
correlated well to the level of renal ischemia. Therefore, we believe increased levels of
urinary L-FABP relate to the presence of a preexisting renal ischemia in patients
undergoing contrast administration. The purpose of the present study was to examine
the clinical signiﬁcance of urinary L-FABP levels before contrast agent administration
in patients with chronic kidney disease (CKD).
Methods: We performed a retrospective study of 215 patients with CKD who
underwent elective catheterization [serum creatinine (Cr) 1.1mg /dl]. Serum Cr and
L-FABP levels were measured immediately before contrast agent administration.
Patients were prospectively followed during a median follow-up period of 755 days
with the end points of Cardiac Cerebral death. CI-AKI was deﬁned as an increase of
0.3 mg/dl (26.5micromol/l) within 2 days of contrast media exposure.
Results: CI-AKI developed in 22 patients (10.2%). High L-FABP levels group
( deﬁned as more than 24.5 microg ⁄ g Cr) was 45 patients and CI-AKI in high L-FABPS22 JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstractlevels group developed in 11patients. A total of 18 cardiac cerebral deaths occurred
during a follow-up period and survival outcome tended to be worse high L-FABP
levels group. (15.9% vs 6.5% P value: 0.045) Kaplan-Meier analysis clearly demon-
strated that patients with high L-FABP levels group were higher rate of cardiac ce-
rebral deaths than those with low L-FABP levels group. (Log rank test:P value:
0.0259).
Conclusion: Urinary L-FABP provides an important information for predicting
CI-AKI and survival outcome before contrast agent administration. These data indi-
cate that urinary L-FABP level is a novel promising marker to provide useful prog-
nostic information for clinical outcomes in patients with chronic kidney disease.
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IVUS Guided Minimum Contrast PCI for CKD Patients
Yoshifumi Hano, Nakamura Shigeru, Tomoko Kobayashi, Atsushi Funatsu,
Masahiro Mizobuchi, Hideaki Takahashi, Munemitsu Otagaki, Satoru Sasaki
Kyoto Katsura Hospital, kyoto, Japan
Background: Estimated safety dose of contrast media for chronic kidney dis-
ease(CKD) patients is computed by the following formula,bodyweight x5/Serum
creatinine(SCr). To reduce the account of contrast media, IVUS guidance throughout
the procedure, would be effective.
Methods: To clarify the efﬁcacy of IVUS guided minimum contrast PCI(MC-PCI) for
CKD patients. From January 2008 to September 2013, consecutive 54 patients of 73
lesions were treated with MC-PCI. Patients with SCr/1.5mg/dl who required elec-
tive PCI based on diagnostic angiogram were enrolled in this study. Hemodialysis
patients were excluded.During PCI, operators manipulated wires without contrast
referring the previous cineangiogram and checked the IVUS. PCI was performed
according with IVUS ﬁndings alone. At the end of the procedure, angiogram was done
with minimal account of contrast media. Contrast induced nephropathy CIN was
diagnosed if SCr level was increased by 0.5 mg/dl within 48 hours.
Results: 45 lesions were treated with stent and 28 lesions were treated with balloon.
Used contrast dose at PCI was signiﬁcantly lower than that of diagnostic CAG
(13.8ml9.2ml VS 39.627.3ml P<0.0001). One case was treated with contrastfree
procedure. Used contrast dose at PCI was 9.36.5% of estimated safety dose. Though,
SCr after 48 hrs showed no increase compared to that of the base line (Pre vs Post
2.10.6 vs 2.10.8 P¼0.438). CIN was found in 2 cases(4%).
Conclusion: IVUS guided MC-PCI minimize CIN in CKD patients. It is comparable
results to that of patients normal renal function.
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Serum Homocysteine Level Inﬂuences on Risk Factor and Severity of Coronary
Artery Disease in Young Patients
Zhu Hang, Xue Hao, Zhang Ming, Chen Si, Wang Guang yi
Chinese People’s Liberation Army General Hospital, Beijing, China
Background: To explore the association between serum homocysteine (Hcy) level
and risk Factor in young patients with coronary heart disease.
Methods: A total of 1455 coronary heart disease patients [(502.4) years, 868male]
hospitalized in our department between June 2011 and March 2013 were included in
this prospective study. Patients were divided into young Coronary heart disease group
(age40, n¼455) and Non youth Coronary heart disease group (age>40, n¼400).
Their serum homocysteine was measured by High Performance Liquid Chromatog-
raphy method.
Results: The serum HCY, TG level of CHD group in young CAD groups were all
higher than those of Non youth CAD groups (P<0.01 or P<0.05), the CAD with
passed history of hypertension and Type-II diabetes of young CHD groups were all
lower than those Non youth group (P<0.01 or P<0.05). The Logistic regression
analysis demonstrated that HCY and history of young CAD were all independent risk
factors for young CHD patients (P<0.01 or P<0.05), while hypertension and diabetes
mellitus were all independent risk factors for Non youth CHD patients (P<0.05).
Conclusion: Higher serum homocysteine is an independent for young CAD patients.Innovative Devices and Futuristic Therapies
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Clinical Efﬁcacy and Safety of Bioresorbable Vascular Scaffold in an Unselected
Patient Population: A Single Centre Real World Experience
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Background: The novel drug-eluting bioresorbable vascular scaffold (BVS) is a
revolutionary treatment option for obstructive coronary artery disease in percutaneouss/ORAL/High Risk Patients: Diabetes, Heart Failure, Renal Failure, Others
